FridayJul 11, 2025 10:00 am

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases

Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities. The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life. For example, malaria claims at least 600,000 lives globally each year, with most of these fatalities happening in low-income countries. Sub-Saharan Africa accounts for approximately 95% of this annual toll. The new test is intended to facilitate rapid diagnostics outside a lab in resource-constrained settings. In low-income countries, healthcare workers often administer treatment without…

Continue Reading

ThursdayJul 10, 2025 9:00 am

New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer

A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%. Glioblastoma, or GBM, is the most common type of brain cancer, and fatalities from this cancer are high. On average, individuals diagnosed with this type of cancer survive for 14 months only. While this link between TBIs and GBM…

Continue Reading

TuesdayJul 08, 2025 10:00 am

Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice

University of Sydney researchers have, for the first time ever, targeted a malfunctioning protein in mice having symptoms akin to Parkinson’s symptoms and successfully improved motor function in the mice. This breakthrough finding could open the door to finding a similar way to treat Parkinson’s disease in humans.  For more than 10 years, the team worked to establish the biological mechanisms which underpin Parkinson’s. Their interest was in uncovering new ways to slow the progression of the disease or even treat it.  In 2017, they published research documenting SOD1 protein abnormalities within the brain and showed that these abnormalities were…

Continue Reading

TuesdayJul 08, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA. Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression. HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49%…

Continue Reading

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

Continue Reading

MondayJul 07, 2025 9:05 am

20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS

Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid.  Advisers to the HHS Secretary ordered CMS officials to release private data, including names, immigration status, social security numbers, addresses, as well as claims data by those enrollees in several jurisdictions, such as Washington State, Illinois, Washington, D.C., and California to the Department of Homeland Security (DHS). The states included in the data sharing request were selected because those…

Continue Reading

ThursdayJul 03, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management NTRB boosting their profile and credibility with its recent membership to the Russel Indexes The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe…

Continue Reading

ThursdayJul 03, 2025 10:00 am

Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.  The researchers focused on Fas Ligand, an immune protein that helps in attacking tumor cells. This protein is present in both human and non-human primates like chimpanzees. The scientists discovered that in humans, a small mutation makes FasL to be easily deactivated by a tumor-linked enzyme called…

Continue Reading

WednesdayJul 02, 2025 9:45 am

Adageis: An AI-Powered Advocate for Healthcare Providers

Adageis, a company offering a powerful and patented AI-centric software solution, remains committed to streamlining the healthcare sector, making it easier for providers to meet their financial goals It works with over 90 Electronic Health Record platforms, an unrivalled level of access that gives its users actionable insights at the point of care The company covers over 260,000 patient lives, and looks to double that to 580,000, achieving its $100,000 monthly recurring revenue target Adageis, a company offering powerful and patented AI-based software, provides flexible healthcare and related software solutions for providers and healthcare systems. The company remains committed to…

Continue Reading

WednesdayJul 02, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim. Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity. Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026. In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000